HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 4, 2003, Pages 439-447

  Monno, Laura ^a   Saracino, Annalisa ^b   Scudeller, Luigia ^c   Pastore, Giuseppe ^a   Bonora, Stefano ^c   Cargnel, Antonietta ^d   Carosi, Gianpiero ^e   Angarano, Gioacchino ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Genotype; Lopinavir; Phenotype; Resistance

Indexed keywords

LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; ENZYME INHIBITION; EXPERIENCE; FEMALE; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS REPLICATION;

EID: 0038298323     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200308010-00004     Document Type: Article

References (28)

1. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224.
2. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75:7462-7469.
3. Kempf DJ, Isaacson JD, King MS, et al. Interpretation of genotypic resistance to ABT-378/ritonavir (ABT-378/r) in protease inhibitor experienced patients using the ABT-378 mutation score [abstract P333]. 5th International Congress on Drug Therapy in HIV infection; Glasgow, Scotland; October 22-26, 2000
4. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther. 2002;7:165-174.
5. Calvez V, Cohen-Codar I, Marcellin AG, et al. Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy [abstract 82]. 5th International Workshop on HIV Drug Resistance & Treatment Strategies; Scottsdale, Arizona; June 4-8, 2001.
6. Molla A, Brun S, Garren K, et al. Patterns of resistance to lopinavir in protease inhibitor-experienced patients following viral rebound during lopinavir/ritonavir therapy [abstract 64]. 5th International Workshop on HIV Drug Resistance & Treatment Strategies. Scottsdale, Arizona; June 4-8, 2001.
7. D'Aquila RT, Schapiro JM, Brun-Vézinet F, et al. Drug resistance mutations in HIV-1. Topics in HIV Medicine. 2002;10:21-25.
8. Prado JC, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS. 2002;16:1009-1017.
9. Saracino A, Angarano G. Change of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen) [abstract 237]. 6th International Congress on Drug Therapy in HIV Infection; Glasgow. Scotland: November 17-21. 2002.
10. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269:729-730.
11. Zolopa AR, Shafer RW, Warford A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999;131:813-821.
12. Deeks SG, Hellmann HS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999;179:1375-1381.
13. Durant J, Clevenbergh P, Halfon S, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-2199.
14. Baxter JL, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83-F93.
15. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209-218.
16. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-588.
17. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
18. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
19. R) in antiretroviral-naïve HIV+ patients: 4-year follow-up [abstract H-165]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; September 2002.
20. de Mendoza C, Martin-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials. 2002;3:304-309.
21. Gilleece YC, Qazi NA, Morlese JF, et al. The efficacy of lopinavir in individuals experiencing protease inhibitor failure. J Acquir Immune Defic Syndr. 2003;32:238-239.
22. Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002;46:2926-2932.
23. Mangum EM, Graham KK. Lopinavir-ritonavir: a new protease inhibitor. Pharmacotherapy. 2001;21:1352-1363.
24. Kempf D, Brun S, Rode R, et al. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naive patients [abstract 89]. 4th International Workshop on HIV Drug Resistance and Treatment Strategies; Sitges, Spain; June 12-16, 2000.
25. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270-8276.
26. Voigt E, Wasmuth JC, Braitinger D, et al. Safety, efficacy and resistance profile under the new protease inhibitor lopinavir/ritonavir: 48 week results [abstract TuPeB4458]. 14th International AIDS Conference; Barcelona, Spain; July 7-12, 2002.
27. Martínez-Picado J, Savara A, Sutton L, et al. Replicative fitness of protease inhibitor-resistant mutants of HIV-1. J Virol. 1999;73:3744-3752.
28. Ziermann R, Limoli K, Das K, et al. A mutation in HIV-1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol. 2000;74:4414-4419.